Results 41 to 50 of about 1,782,190 (315)

Controlled Release Bilayer Floating Effervescent and Noneffervescent Tablets Containing Levofloxacin and Famotidine

International Journal of Polymer Science
The present study is aimed at designing bilayer-floating tablets to improve the drug concentration in the stomach for enhanced therapeutic efficacy. The tablets are comprised of an upper layer of levofloxacin (466.5 mg) and a lower layer of famotidine ...
Muhammad Tufail, Kifayat Ullah Shah, Ikram Ullah Khan, Kamran Ahmad Khan, Shefaat Ullah Shah, Faisal Rashid, Jahangir Khan, Abdulrahman Alshammari, Abdullah F. Alasmari, Muhammad Shahid Riaz   +9 more
doaj   +1 more source

Rational Drug Design Rational Drug Design

, 2017
For the past three decades rationale drug design (RDD) has been developing as an innovative, rapid and successful way to discover new drug candidates. Many strategies have been followed and several targets with diverse structures and different biological roles have been investigated. Despite the variety of computational tools available, one can broadly
Khaled H. Barakat, Michael Houghton, D. Lorne Tyrrel, Jack A. Tuszynski   +3 more
openaire   +1 more source

Claudin‐6 Protein Expression in Atypical Teratoid/Rhabdoid Tumors Is Strongly Enriched in the Molecular Subgroup AT/RT‐TYR

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Claudin‐6 has emerged as a promising immunotherapeutic target, yet protein‐level data in atypical teratoid/rhabdoid tumors (AT/RTs) have been inconsistent. We analyzed 36 well‐characterized AT/RT samples and found membranous claudin‐6 protein expression in 58% of cases, with striking enrichment in the molecular subgroup AT/RT‐TYR (100%) and ...
Victoria E. Fincke, Christian Thomas, Michael C. Frühwald, Pascal D. Johann, Martin Hasselblatt   +4 more
wiley   +1 more source

2D-QSAR driven design, molecular docking, molecular dynamics simulation and MM/GBSA studies on quinazoline derivatives for development of VEGFR-2 inhibitors

Discover Chemistry
Various in silico approaches were utilized to design quinazoline derivatives as anticancer agents targeting VEGFR-2. Six 2D-QSAR models were generated via Monte Carlo optimization method of CORALSEA software.
Mayank Kashyap, Saurabh Gupta, Yogita Bansal, Gulshan Bansal   +3 more
doaj   +1 more source

Production of IgG1-based bispecific antibody without extra cysteine residue via intein-mediated protein trans-splicing

Scientific Reports, 2021
A major class of bispecific antibodies (BsAbs) utilizes heterodimeric Fc to produce the native immunoglobulin G (IgG) structure. Because appropriate pairing of heavy and light chains is required, the design of BsAbs produced through recombination or ...
Hiroki Akiba, Tomoko Ise, Satoshi Nagata, Haruhiko Kamada, Hiroaki Ohno, Kouhei Tsumoto   +5 more
doaj   +1 more source

DXS as a target for structure-based drug design [PDF]

, 2017
In this review, we analyze the enzyme DXS, the first and rate-limiting protein in the methylerythritol 4-phosphate pathway. This pathway was discovered in 1996 and is one of two known metabolic pathways for the biosynthesis of the universal building ...
Diamanti, Eleonora, Anna KH Hirsch, Carsten Wrenger, Groves, Matthew R, Redeem, Eswar, Gierse, Robin Matthias, Hirsch, Anna K. H., Eswar Redeem, Hirsch, Anna Kh, Matthew R Groves, Wrenger, Carsten, Groves, Matthew R.; id_orcid, Robin Matthias Gierse, Groves, Matthew R., Eleonora Diamanti   +14 more
core   +1 more source

Time Toxicity in Wilms Tumor: Quantifying the Burden of Healthcare Interaction in the First Year After Diagnosis

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Wilms tumor (WT) treatment imposes a significant time burden on patients and their families. Time toxicity is a patient‐centered metric that quantifies the burden of healthcare interaction. We sought to define time toxicity in the first year after diagnosis of WT and hypothesized that it would increase as tumor stage and treatment ...
Caleb Q. Ashbrook, Veerain Gupta, Nicholas J. Clark, Vijay Rings, Lauren E. Corona, Douglass B. Clayton, Daniel J. Benedetti   +6 more
wiley   +1 more source

Angiogenic signaling pathways and anti-angiogenic therapy for cancer

Signal Transduction and Targeted Therapy, 2023
Angiogenesis, the formation of new blood vessels, is a complex and dynamic process regulated by various pro- and anti-angiogenic molecules, which plays a crucial role in tumor growth, invasion, and metastasis.
Zhen-Ling Liu, Huan-Huan Chen, Li-Li Zheng, Li-Ping Sun, Lei Shi   +4 more
doaj   +1 more source

Emapalumab for Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CD19‐Directed CAR‐T in Two Patients With B‐ALL: Clinical and Biomarker Correlates

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS) is a life‐threatening hyperinflammatory toxicity distinct from cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T‐cell (CAR‐T) therapy. In a single‐institution retrospective cohort of pediatric and young adult patients
Thomas J. Galletta, Jeremy D. Rubinstein, Christopher E. Dandoy, Ruby Khoury, Angela Faulhaber, Christine L. Phillips, Christa Krupski   +6 more
wiley   +1 more source

Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 with a highly selective inhibitor for the treatment of prostate cancer

Nature Communications, 2022
The kinase DYRK2 is a known oncogene but its role in prostate cancer is unexplored. Here, the authors identify DYRK2 as a target for prostate cancer with a role in invasion and they discover a specific DYRK2 inhibitor that has good pharmacokinetics and ...
Kai Yuan, Zhaoxing Li, Wenbin Kuang, Xiao Wang, Minghui Ji, Weijiao Chen, Jiayu Ding, Jiaxing Li, Wenjian Min, Chengliang Sun, Xiuquan Ye, Meiling Lu, Liping Wang, Haixia Ge, Yuzhang Jiang, Haiping Hao, Yibei Xiao, Peng Yang   +17 more
doaj   +1 more source